OA22.04 BRIGHTSTAR Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC

Approximately 95% of patients who have an initial response to ALK-TKIs exhibit an incomplete response, resulting in residual disease that may enable emergence of acquired resistance. Minimizing or eliminating residual disease with local consolidative therapy (LCT) may delay development of resistance and improve clinical outcomes.